-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Up 9.8% in December
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Up 9.8% in December
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,800,000 shares, a growth of 9.8% from the November 30th total of 1,640,000 shares. Based on an average trading volume of 306,400 shares, the short-interest ratio is currently 5.9 days. Currently, 6.2% of the company's shares are short sold.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Prairiewood Capital LLC acquired a new position in shares of iTeos Therapeutics in the third quarter worth $615,000. Alps Advisors Inc. acquired a new stake in iTeos Therapeutics in the 2nd quarter valued at about $434,000. Rafferty Asset Management LLC grew its position in shares of iTeos Therapeutics by 2.1% during the second quarter. Rafferty Asset Management LLC now owns 99,368 shares of the company's stock worth $2,047,000 after buying an additional 2,067 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of iTeos Therapeutics by 22.7% during the second quarter. Principal Financial Group Inc. now owns 167,750 shares of the company's stock worth $3,455,000 after buying an additional 31,004 shares during the period. Finally, Virtus ETF Advisers LLC increased its stake in shares of iTeos Therapeutics by 39.1% during the second quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company's stock worth $119,000 after buying an additional 1,629 shares during the period.
Get iTeos Therapeutics alerts:iTeos Therapeutics Price Performance
Shares of NASDAQ:ITOS traded down $0.71 during mid-day trading on Wednesday, reaching $17.83. 2,081 shares of the company were exchanged, compared to its average volume of 384,108. iTeos Therapeutics has a 1 year low of $16.21 and a 1 year high of $47.63. The firm's 50-day simple moving average is $19.84 and its 200 day simple moving average is $21.20. The firm has a market cap of $634.39 million, a price-to-earnings ratio of 2.69 and a beta of 1.38.
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The firm had revenue of $19.49 million for the quarter, compared to analysts' expectations of $42.05 million. iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. On average, research analysts forecast that iTeos Therapeutics will post 2.85 earnings per share for the current fiscal year.iTeos Therapeutics Company Profile
(Get Rating)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Featured Articles
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Apple Stock Pulls Back, Is Now the Time To Buy?
- Is A Short-Squeeze In Mullen Automotive About To Begin?
- AMD is Down 55% Over the Past Year, Is it Time to Buy?
- Is First Solar Stock is Flying Too Close to the Sun?
- What's the Outlook for META Stock in 2023?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ITeos治疗公司(纳斯达克代码:ITOS-GET评级)是空头股数12月份大幅增长的目标。截至12月15日,空头股数共有180万股,比11月30日的164万股增长了9.8%。以平均成交量306,400股计算,目前短息比为5.9天。目前,该公司6.2%的股票被卖空。
机构资金流入和流出
对冲基金和其他机构投资者最近对他们在该业务中的头寸进行了调整。Prairiewood Capital LLC在第三季度收购了iTeos治疗公司价值61.5万美元的新股份。Alps Advisors Inc.在第二季度收购了iTeos治疗公司的新股份,价值约为43.4万美元。第二季度,Rafferty Asset Management LLC在iTeos Treeutics的股票头寸增加了2.1%。Rafferty Asset Management LLC现在持有99,368股该公司股票,价值2,047,000美元,上个季度又购买了2,067股。信安金融集团在第二季度增持了iTeos治疗公司的股份22.7%。在此期间,信安金融集团又购买了31,004股,目前持有167,750股该公司股票,价值3,455,000美元。最后,Virtus ETF Advisers LLC在第二季度将其在iTeos治疗公司的股份增加了39.1%。Virtus ETF Advisers LLC在此期间又购买了1,629股,现在拥有5,790股该公司股票,价值11.9万美元。
到达ITeos治疗公司警报:ITeos治疗药物的性价比
周三午盘,新浪纳斯达克股价下跌0.71美元,至17.83美元。该公司的股票成交量为2,081股,而平均成交量为384,108股。ITeos治疗公司的一年低点为16.21美元,一年高位为47.63美元。该公司50日简单移动均线切入位为19.84美元,200日简单移动均线切入位为21.20美元。该公司市值为6.3439亿美元,市盈率为2.69倍,贝塔系数为1.38。
ITOS治疗公司(纳斯达克代码:ITOS-GET Rating)最近一次发布季度收益报告是在11月10日星期四。该公司公布本季度每股收益为0.03美元,低于普遍预期的0.07美元(0.04美元)。该公司当季营收为1,949万美元,高于分析师预期的4,205万美元。ITeos治疗公司的股本回报率为42.62%,净利润率为57.48%。研究分析师平均预测,iTeos治疗公司本财年每股收益将达到2.85美元。ITeos治疗公司简介
(获取评级)
ITeos治疗公司是一家临床阶段的生物制药公司,致力于为患者发现和开发免疫肿瘤疗法。该公司的产品线包括处于第二阶段临床试验的腺苷A2AR拮抗剂的小分子拮抗剂InupAdant,以及处于第1/2阶段临床试验的TIGIT或具有Ig和ITIM结构域的T细胞免疫受体拮抗剂EOS-448,以及用于激活树突状细胞和巨噬细胞并促进抗体依赖的细胞毒性或ADCC活性的Fc?R。
专题文章
- 免费获取StockNews.com关于iTeos治疗的研究报告(ITOS)
- 苹果股价回落,现在是买入的时候了吗?
- 马伦汽车(Mullen Automotive)的挤兑即将开始?
- AMD在过去一年里下跌了55%,是时候买入了吗?
- 第一太阳能股票是不是飞得离太阳太近了?
- 2023年元股票的前景如何?
接受iTeos治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对iTeos治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧